Crescent Biopharma, Inc. (CBIO) Stock

Crescent Biopharma, Inc. (CBIO) is a Healthcare stock trading at $17.65 (as of 2026-06-18), with a market capitalization of $569.36M and a trailing P/E of -30.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates. Its pipeline includes oncology antibodies such as CR-001, along with CR-002 and CR-003, and it works with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on development and commercialization of oncology therapeutics.

Valuation — source: SEC EDGAR (first-party)
Price$17.65
Market Cap$569.36M
P/E Ratio-30.4
EV / EBITDA-1.7
Price / Book2.69
Price / Sales41.58
DCF Value (model)$-37.02
DCF Upside vs Price-309.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$10.84M
Net Margin-1419.6%
Return on Equity-95.1%
Current Ratio13.78
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)1.7%
FCF Growth (YoY)-10.9%
Financial Health — source: SEC EDGAR
Altman Z-Score5.78 (safe)
Valuation vs Sector & Industry
Stock P/E-30.4
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-245.4%
vs Industry-278.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($75.93M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJoshua T. Brumm
Employees41
CountryUS
IPO Date2014-01-10

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Avalo Therapeutics, Inc. (AVTX)
  • Neurogene Inc. (NGNE)
  • AC Immune S.A. (ACIU)
  • CAMP4 Therapeutics Corporation (CAMP)
  • Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
  • Allogene Therapeutics, Inc. (ALLO)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Aldeyra Therapeutics, Inc. (ALDX)
CBIO earnings history · CBIO institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.